Credit Suisse Upgrades Biogen (BIIB) to Outperform
Tweet
Share
E-mailGet Alerts BIIB Hot Sheet
Price: $218.50 -1.35%
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 6 | Down: 5 | New: 3
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 6 | Down: 5 | New: 3
Join SI Premium – FREE
Credit Suisse upgraded Biogen (NASDAQ: BIIB) from Neutral to Outperform. PT increased from $100 to $126.
For more ratings news on Biogen click here and for the rating history of Biogen click here.
Shares of Biogen closed at $98.65 yesterday.
For more ratings news on Biogen click here and for the rating history of Biogen click here.
Shares of Biogen closed at $98.65 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nomura/Instinet Upgrades Zeon Corp (4205:JP) (ZEOOF) to Buy
- Goldman Sachs Upgrades Bapcor Ltd. (BAP:AU) to Neutral
- Citi Upgrades Genius Electronic Optical Co Ltd (3406:TT) to Buy
Create E-mail Alert Related Categories
UpgradesRelated Entities
Credit SuisseSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
